腎臓がんの治療と診断の世界市場

腎臓がんの治療と診断の世界市場は2030年までに79億米ドルに到達

2024年に67億米ドルと推定される腎臓がんの治療と診断の世界市場は、2024～2030年の分析期間においてCAGR 2.7%で成長し、2030年には79億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである明細胞RCCがんは、CAGR 2.7%を記録し、分析期間終了までに22億米ドルに達すると予測されます。乳頭状RCCがんセグメントの成長率は、分析期間中CAGR 2.1%と推定されます。

米国市場は18億米ドルと推定、中国はCAGR 5.1％で成長予測

米国の腎臓がんの治療と診断市場は2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに15億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.0％と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界の腎臓がんの治療と診断市場- 主要動向と促進要因まとめ

なぜ腎臓がんはがん治療薬において戦略的重要性を増しているのか？

腎臓がんは、その世界の有病率の増加、複雑な分子病因学、および治療法のスペクトルの拡大により、腫瘍学治療における焦点として浮上しています。腎細胞がん（RCC）は腎臓の悪性腫瘍の約85～90％を占め、特に高所得国では罹患率、死亡率ともに上昇しています。この疾患は従来の化学療法に抵抗性を示すため、標的療法、免疫チェックポイント阻害剤、個別化分子プロファイリングに治療の軸足を移しています。その結果、主要なバイオファーマ企業は、革新的な作用機序、バイオマーカー主導型治療、免疫療法とチロシンキナーゼ阻害剤（TKI）の併用に投資し、治療パラダイムを根本的に再構築しています。

画像診断と分子診断の技術的進歩は、特に喫煙者、肥満者、腎悪性腫瘍の家族歴のある人などの高リスク群における腎がんの早期発見とリスク層別化を再定義しつつあります。マルチパラメトリックMRI、PETベースのトレーサー、新規の循環腫瘍DNA（ctDNA）アッセイは、非侵襲的な診断・モニタリングツールとして臨床的な支持を得ています。その結果、診断の精度が向上し、腫瘍医が疾患進行の早い段階で標的治療を実施できるようになっています。一方、放射線医学における人工知能の統合は、臨床医が腎腫瘤の良性・悪性をより高い感度で区別するのに役立っており、治療計画や転帰予測に直接影響を与えています。

免疫腫瘍学とプレシジョン・メディシンによって、治療アルゴリズムはどのように進化しているのか？

腎がんの治療枠組みは、転移性RCCの最前線治療薬として登場した免疫チェックポイント阻害薬（ICI）を取り入れることで急速に進化しています。ニボルマブ＋イピリムマブやペムブロリズマブ＋アキシチニブなどの併用療法は、現在ではゴールドスタンダードレジメンとみなされており、複数の試験で生存期間の有意な延長が証明されています。これらの進歩は、単剤アプローチから、血管内皮増殖因子（VEGF）経路を標的としながら免疫回避機構を調節するようにデザインされたコンビナトリアルプロトコールへの移行を強調しています。低酸素誘導性因子2α（HIF-2α）とMET阻害剤を標的とするいくつかの新規薬剤も後期臨床試験段階にあり、治療ツールボックスのさらなる拡大を目指しています。

個別化医療は、腎臓がんの薬剤開発と臨床試験デザインにますます影響を及ぼしています。次世代シークエンシング（NGS）プラットフォームは、ドライバー変異や実用的なバイオマーカーの同定に使用され、精密治療の割り当てや適応投与レジメンを可能にしています。さらに、観察登録や縦断的データプラットフォームから得られる実世界のエビデンスが、治療の順序付けや毒性管理を改良するのに役立っており、新たな治療法が有効性だけでなく、耐久性やQOLによっても評価されるようになっています。このような患者中心の生物学的治療へのシフトは、市場の競争力学を再定義しつつあり、バイオテクノロジー革新企業や製薬大手は、有効性と個別化適用可能性の両方を通じて提供する製品の差別化を図っています。

診断イノベーションとバイオマーカー戦略は市場拡大においてどのような役割を果たすか？

診断学の進歩は、早期発見、より良い病期分類、治療効果の動的モニタリングを可能にすることで、腎臓がん市場の拡大において極めて重要な役割を果たしています。特にctDNA、無細胞DNA、エクソソームRNAを測定するリキッドバイオプシー・プラットフォームは、非侵襲的なサーベイランスや残存病変の追跡のために採用されるようになってきています。これらのアッセイは、特に転移性疾患において、病勢進行や治療抵抗性の予測に有用であることが証明されつつあります。さらに、プロテオミクスとメタボロミクスのプロファイリングが診断ワークフローに統合され、特異性を向上させ、適切な治療経路のために患者を層別化しています。

ラジオミクスとAI主導の画像解析は、CTやMRIスキャンから腫瘍の攻撃性や免疫療法の反応性と相関する定量的特徴を抽出することで、腎臓がん診断に革命をもたらしています。機械学習アルゴリズムは、病理学的サブタイプ、血管新生レベル、免疫学的マーカーを予測するために大規模な画像データセットで訓練されており、放射線科医や腫瘍内科医に意思決定支援ツールを提供しています。一方、診断試薬メーカーやプラットフォームメーカーは、RCCに特化したマルチプレックス免疫組織化学（IHC）キットやNGSパネルに対する需要の高まりを目の当たりにしています。これらのプラットフォームは臨床研究やトランスレーショナルリサーチのニーズをサポートし、研究機関での購入やラボ開発試験（LDT）の承認を後押ししています。

さらに、患者へのアドボカシーや啓発キャンペーンは、診断の普及に一役買っています。受診率の低い地域では、国のがん対策計画にRCCに焦点を当てた啓発、スクリーニング、早期介入政策が盛り込まれつつあります。このような公衆衛生対策は、分子診断に対する保険適用率の上昇と相まって、がん診断ラボにおける患者の処理能力にプラスの影響を与えています。市場が成熟するにつれ、診断技術のクロスライセンスや製薬企業と診断薬企業のコンパニオン診断（CDx）提携が急増し、治療と診断の緊密な連携が可能になり、対応可能な患者集団が拡大すると予想されます。

世界各地域の市場成長を牽引する要因とは？

世界の腎臓がんの治療と診断市場の成長は、腎悪性腫瘍の発生率の増加、治療イノベーションの拡大、精密診断へのアクセスの拡大など、いくつかの要因によって牽引されています。北米、欧州、中国やインドなどの新興市場では、肥満、高血圧、喫煙率の上昇により、RCCの疫学的負担が増大しています。このような罹患率の上昇は、治療開始率の上昇や高度診断薬に対する幅広い需要につながっています。さらに、人口の高齢化と医療インフラの改善により、以前は十分なサービスを受けられなかった地域でもがん診断が利用しやすくなっています。

政府による資金援助や有利な薬事規制により、新規治療法や診断薬の臨床研究、迅速な承認、償還が加速しています。FDAやEMAなどの機関は、腎臓がんの有望な治療法に対して画期的治療法の指定や条件付き承認を行い、革新的な候補薬の市場投入までの時間を短縮しています。さらに、学術機関、産業界、公衆衛生機関が関与するマルチ利害関係者連携により、世界の臨床試験ネットワークが強化され、多様な患者コホートの登録が容易になり、強固な臨床エビデンスの創出が支援されています。

商業面では、標的治療に合わせたCDxソリューションを共同開発するための製薬企業と診断薬企業の戦略的提携が市場に利益をもたらしています。PD-L1発現、MET変化、血管新生バイオマーカーを同定するコンパニオン診断薬は、特定の治療レジメンに患者を層別化するのに役立ち、臨床転帰と支払者の受容性を高めています。さらに、特に北米とアジア太平洋地域では、患者が遠隔地から分子プロファイリングサービスにアクセスできるようにする、DTC検査と遠隔腫瘍学プラットフォームが破壊的な力として台頭してきています。これらの力学を総合すると、腎臓がんの治療と診断市場は今後10年間にわたってイノベーション主導の持続的成長を遂げることになります。

セグメント

がん種（透明細胞RCCがん、乳頭状RCCがん、色素芽細胞RCCがん、尿路上皮がん／移行細胞がん、ウィルムス腫瘍がん、腎肉腫がん、集合管RCCがん、その他の腎臓がん）、診断（生検診断、画像検査診断、血液検査診断、その他の診断）

調査対象企業の例

• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Bristol-Myers Squibb
• Caris Life Sciences
• Cigna Healthcare
• Clovis Oncology
• Eisai Co., Ltd.
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd.
• Genentech
• GlaxoSmithKline plc（GSK）
• Illumina, Inc.
• Ipsen
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Promega Corporation
• Siemens Healthineers
• Thermo Fisher Scientific

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Kidney Cancer Therapeutics and Diagnostics Market to Reach US$7.9 Billion by 2030

The global market for Kidney Cancer Therapeutics and Diagnostics estimated at US$6.7 Billion in the year 2024, is expected to reach US$7.9 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Clear Cell RCC Cancer, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Papillary RCC Cancer segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 5.1% CAGR

The Kidney Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Kidney Cancer Therapeutics And Diagnostics Market - Key Trends & Drivers Summarized

Why Is Kidney Cancer Gaining Strategic Significance in Oncology Therapeutics?

Kidney cancer is emerging as a focal point within the oncology therapeutics landscape due to its increasing global prevalence, complex molecular etiology, and expanding spectrum of treatment modalities. Renal cell carcinoma (RCC) constitutes approximately 85-90% of all kidney malignancies and has demonstrated both rising incidence and mortality rates, particularly in high-income nations. The disease's resistance to traditional chemotherapies has prompted a therapeutic pivot toward targeted therapies, immune checkpoint inhibitors, and personalized molecular profiling. Consequently, major biopharma companies are investing in innovative mechanisms of action, biomarker-driven treatments, and combinations of immunotherapy and tyrosine kinase inhibitors (TKIs), fundamentally reshaping the therapeutic paradigm.

Technological advances in imaging and molecular diagnostics are redefining the early detection and risk stratification of kidney cancer, particularly among high-risk groups such as smokers, obese individuals, and those with a family history of renal malignancy. Multiparametric MRI, PET-based tracers, and novel circulating tumor DNA (ctDNA) assays are gaining clinical traction as non-invasive diagnostic and monitoring tools. As a result, diagnostic precision is improving, allowing oncologists to deploy targeted therapies earlier in the disease progression. Meanwhile, the integration of artificial intelligence in radiology is helping clinicians distinguish between benign and malignant renal masses with greater sensitivity, directly impacting treatment planning and outcome forecasting.

How Are Treatment Algorithms Evolving Through Immuno-Oncology and Precision Medicine?

The therapeutic framework for kidney cancer is rapidly evolving through the incorporation of immune checkpoint inhibitors (ICIs), which have emerged as frontline treatments for metastatic RCC. Combinations such as nivolumab plus ipilimumab or pembrolizumab plus axitinib are now considered gold standard regimens, with multiple studies demonstrating significant survival benefits. These advances underscore the transition from single-agent approaches to combinatorial protocols designed to modulate immune evasion mechanisms while targeting vascular endothelial growth factor (VEGF) pathways. Several novel agents targeting hypoxia-inducible factor 2 alpha (HIF-2α) and MET inhibitors are also in late-stage clinical trials, aiming to further expand the therapeutic toolbox.

Personalized medicine is increasingly influencing drug development and clinical trial design in kidney cancer. Next-generation sequencing (NGS) platforms are being used to identify driver mutations and actionable biomarkers, enabling precision treatment allocation and adaptive dosing regimens. Furthermore, real-world evidence from observational registries and longitudinal data platforms is helping refine treatment sequencing and toxicity management, ensuring that emerging therapies are evaluated not only by efficacy but also by durability and quality of life. This shift toward patient-centered, biology-driven care is redefining the competitive dynamics of the market, as biotech innovators and pharmaceutical giants seek to differentiate their offerings through both efficacy and personalized applicability.

What Role Do Diagnostic Innovations and Biomarker Strategies Play in Market Expansion?

Advancements in diagnostics are playing a pivotal role in kidney cancer market expansion by enabling earlier detection, better staging, and dynamic monitoring of treatment response. Liquid biopsy platforms, particularly those measuring ctDNA, cell-free DNA, and exosomal RNA, are increasingly adopted for non-invasive surveillance and residual disease tracking. These assays are proving valuable in predicting disease progression and therapeutic resistance, especially in the metastatic setting. Additionally, proteomic and metabolomic profiling are being integrated into diagnostic workflows to improve specificity and stratify patients for appropriate therapeutic pathways.

Radiomics and AI-driven imaging analytics are revolutionizing kidney cancer diagnostics by extracting quantitative features from CT and MRI scans that correlate with tumor aggressiveness and immunotherapy responsiveness. Machine learning algorithms are being trained on large image datasets to predict pathological subtypes, angiogenesis levels, and immunological markers-thus offering decision-support tools for radiologists and oncologists. Meanwhile, diagnostic reagent and platform manufacturers are witnessing increased demand for multiplex immunohistochemistry (IHC) kits and NGS panels specific to RCC. These platforms support clinical and translational research needs, driving institutional purchases and lab-developed test (LDT) approvals.

Moreover, patient advocacy and awareness campaigns are playing a role in increasing diagnostic uptake. In regions with under-screened populations, national cancer control plans are now incorporating RCC-focused awareness, screening, and early intervention policies. These public health measures, combined with rising insurance coverage for molecular diagnostics, are positively influencing patient throughput in cancer diagnostic labs. As the market matures, cross-licensing of diagnostic technologies and companion diagnostic (CDx) partnerships between pharma and diagnostic companies are expected to surge, enabling tighter therapeutic-diagnostic alignment and expanding addressable patient populations.

What Factors Are Driving Market Growth Across Global Regions?

The growth in the global kidney cancer therapeutics and diagnostics market is driven by several factors, including the increasing incidence of renal malignancies, expanding therapeutic innovations, and growing access to precision diagnostics. The epidemiological burden of RCC is intensifying in North America, Europe, and emerging markets like China and India due to rising obesity, hypertension, and smoking prevalence. This rising incidence is translating into higher treatment initiation rates and broader demand for advanced diagnostics. Moreover, aging populations and improved healthcare infrastructure are making cancer diagnostics more accessible in previously underserved regions.

Government funding initiatives and favorable regulatory pathways are accelerating clinical research, fast-track approvals, and reimbursement coverage for novel therapies and diagnostics. Agencies such as the FDA and EMA are providing breakthrough therapy designations and conditional approvals for promising therapies in kidney cancer, shortening time-to-market for innovative candidates. Furthermore, multi-stakeholder collaborations involving academic institutions, industry, and public health bodies are strengthening global trial networks and facilitating the enrollment of diverse patient cohorts, thereby supporting robust clinical evidence generation.

On the commercial side, the market is benefiting from strategic alliances between pharmaceutical and diagnostic companies to co-develop CDx solutions tailored to targeted therapies. Companion diagnostics that identify PD-L1 expression, MET alterations, or angiogenesis biomarkers are helping stratify patients for specific therapeutic regimens, enhancing clinical outcomes and payer acceptance. Additionally, direct-to-consumer testing and tele-oncology platforms are emerging as disruptive forces, particularly in North America and Asia-Pacific, enabling patients to access molecular profiling services remotely. Collectively, these dynamics are positioning the kidney cancer therapeutics and diagnostics market for sustained, innovation-led growth over the next decade.

SCOPE OF STUDY:

The report analyzes the Kidney Cancer Therapeutics and Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer, Other Kidney Cancers); Diagnostics (Biopsy Diagnostics, Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Bristol-Myers Squibb
• Caris Life Sciences
• Cigna Healthcare
• Clovis Oncology
• Eisai Co., Ltd.
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd.
• Genentech
• GlaxoSmithKline plc (GSK)
• Illumina, Inc.
• Ipsen
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Promega Corporation
• Siemens Healthineers
• Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Kidney Cancer Therapeutics and Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Renal Cell Carcinoma Throws the Spotlight on Early Detection Technologies
  • Advancements in Immuno-Oncology Therapies Propel Growth in Targeted Kidney Cancer Treatments
  • Growing Adoption of Liquid Biopsies Expands Diagnostic Accuracy and Market Scope
  • FDA Approvals for Novel Drug Combinations Strengthen Business Case for First-Line Therapies
  • Patient Stratification via Genomic Profiling Drives Adoption of Precision Therapeutics
  • Expansion of Cancer Screening Programs in Developing Economies Generates Demand for Diagnostic Kits
  • Emergence of Companion Diagnostics Spurs Integration of Therapeutics and Testing Platforms
  • Shift Toward Minimally Invasive Biopsy Procedures Accelerates Market Penetration
  • Growing Clinical Pipeline of VEGF and mTOR Inhibitors Fuels Therapeutic Innovation
  • Increasing Investment in Cancer Immunotherapy Expands Addressable Market Opportunity
  • Rising Awareness of Kidney Health in Aging Populations Sustains Demand for Screening Solutions
  • Strategic Collaborations Between Pharma and Diagnostic Firms Drive Technology Integration
  • Reimbursement Reforms for Oncology Care Strengthen Access to Premium Diagnostics and Drugs
  • Integration of AI in Radiological Imaging Enhances Detection and Monitoring of Renal Tumors
  • Rising Use of Biomarkers for Recurrence Prediction Spurs R&D in Molecular Diagnostics
  • Hospital Infrastructure Modernization Drives Adoption of Advanced Diagnostic Equipment
  • Regulatory Fast-Track Approvals Propel Commercialization of Promising Therapeutics
  • Global Focus on Personalized Oncology Care Catalyzes Adoption of Genomics-Based Therapies
  • Challenges in Drug Pricing and Access Pose Barriers to Widespread Therapeutic Uptake
  • Expansion of Cancer Registries and Databases Bolsters Data-Driven R&D in Kidney Cancer
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Kidney Cancer Therapeutics and Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Clear Cell RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Clear Cell RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Clear Cell RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Papillary RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Papillary RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Papillary RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Chromophobe RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Chromophobe RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Chromophobe RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Urothelial Carcinoma / Transitional Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Urothelial Carcinoma / Transitional Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Urothelial Carcinoma / Transitional Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Wilms Tumor Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Wilms Tumor Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Wilms Tumor Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Renal Sarcoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Renal Sarcoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Renal Sarcoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Collecting Duct RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Collecting Duct RCC Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Collecting Duct RCC Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Kidney Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Kidney Cancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Other Kidney Cancers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Imaging Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Imaging Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Imaging Tests Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Blood Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Blood Tests Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Blood Tests Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Other Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Biopsy Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Biopsy Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Biopsy Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• JAPAN
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• CHINA
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: China 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• EUROPE
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• FRANCE
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: France 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: France 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• GERMANY
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 80: Germany Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Germany Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Germany 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Germany 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 86: Italy Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Italy Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Italy 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 89: Italy Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Italy Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Italy 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 92: UK Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: UK Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: UK 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 95: UK Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: UK Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: UK 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 98: Spain Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Spain Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Spain 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 101: Spain Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Spain Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Spain 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 104: Russia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Russia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Russia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 107: Russia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Russia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Russia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Rest of Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Rest of Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Rest of Europe Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Rest of Europe 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 125: Australia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Australia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Australia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 128: Australia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Australia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Australia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• INDIA
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 131: India Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: India Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: India 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 134: India Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: India Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: India 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 137: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: South Korea Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: South Korea 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 140: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: South Korea Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: South Korea 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Asia-Pacific Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 152: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 155: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 158: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Argentina Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Argentina 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 161: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Argentina Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Argentina 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 164: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Brazil Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Brazil 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 167: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Brazil Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Brazil 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 170: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Mexico Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Mexico 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 173: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Mexico Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Mexico 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Rest of Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Latin America Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Rest of Latin America 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 185: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 188: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 191: Iran Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Iran Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Iran 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 194: Iran Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Iran Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Iran 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 197: Israel Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Israel Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Israel 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 200: Israel Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Israel Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Israel 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Saudi Arabia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Saudi Arabia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Saudi Arabia Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Saudi Arabia 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 209: UAE Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: UAE Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: UAE 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 212: UAE Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: UAE Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: UAE 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Rest of Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Rest of Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Rest of Middle East Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Rest of Middle East 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030
• AFRICA
  • Kidney Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 221: Africa Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Africa Historic Review for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Africa 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Clear Cell RCC Cancer, Papillary RCC Cancer, Chromophobe RCC Cancer, Urothelial Carcinoma / Transitional Cell Carcinoma, Wilms Tumor Cancer, Renal Sarcoma Cancer, Collecting Duct RCC Cancer and Other Kidney Cancers for the Years 2014, 2025 & 2030
  • TABLE 224: Africa Recent Past, Current & Future Analysis for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Africa Historic Review for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Africa 16-Year Perspective for Kidney Cancer Therapeutics and Diagnostics by Diagnostics - Percentage Breakdown of Value Sales for Imaging Tests Diagnostics, Blood Tests Diagnostics, Other Diagnostics and Biopsy Diagnostics for the Years 2014, 2025 & 2030

IV. COMPETITION